

## Cellular Biomedicine Group Appoints CAR-T Pioneer as Member of Scientific Advisory Board

18 December 2018 | News

Dr. Stephan A. Grupp, a CAR-T pioneer and pediatric oncologist, is appointed as a member of CBMG's Scientific Advisory Board to impart scientific vigor and clinical guidance in the Company's immuno-oncology pipeline



Cellular Biomedicine Group, a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, has announced the appointment of Dr. Stephan A. Grupp, a CAR-T pioneer and pediatric oncologist, to CBMG's Scientific Advisory Board to impart scientific vigor and clinical guidance in the Company's immuno-oncology pipeline.

"Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher. His decades of work and achievements have had a significant impact on the groundbreaking field of CAR-T therapy," commented Tony (Bizuo) Liu, Chief Executive Officer for the Company. "He will advise us on our scientific and clinical studies for pediatric and hematologic related cancers. Dr. Grupp joins our team of seasoned scientific advisors, whose expertise, along with CBMG's solid pre-clinical work and world-class manufacturing processes will advance the development of these transformative therapies."

Dr. Stephan A. Grupp, M.D., Ph.D., has been Chief of Section - Cellular Therapy and Transplant in Oncology Division at The Children's Hospital of Philadelphia (CHOP) since June 1, 2017. Dr. Grupp has researched and led groundbreaking clinical trials of CD19-directed CAR-T cell therapy for children with acute lymphoblastic leukemia (ALL). He serves as Medical Director of the Stem Cell Laboratory at CHOP. He has been an attending physician and oncology researcher at CHOP since 1996, and is a Professor of Pediatrics and the University of Pennsylvania Perelman School of Medicine.

Dr. Grupp's outstanding contribution to oncology is in the clinical development of chimeric antigen receptor CAR T cell (CAR-T) therapy for relapsed and refractory ALL in children and young adults. He is the Director of the Cancer Immunotherapy Program and Director of Translational Research for the Center for Childhood Cancer Research. Working with U Penn Cancer Center, he did many of the preclinical in vivo studies and then developed the first pediatric trial and treated the first pediatric patient at CHOP with CAR-T cell therapy in 2012.

Cellular Biomedicine Group, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory.